Collegium Pharmaceutical Stock Beta
| COLL Stock | USD 37.51 0.27 0.71% |
Collegium Pharmaceutical fundamentals help investors to digest information that contributes to Collegium Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Collegium Stock. The fundamental analysis module provides a way to measure Collegium Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Collegium Pharmaceutical stock.
Collegium | Beta |
Collegium Pharmaceutical Company Beta Analysis
Collegium Pharmaceutical's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Collegium Pharmaceutical Beta | 1.05 |
Most of Collegium Pharmaceutical's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Collegium Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Collegium Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Collegium Pharmaceutical is extremely important. It helps to project a fair market value of Collegium Stock properly, considering its historical fundamentals such as Beta. Since Collegium Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Collegium Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Collegium Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Collegium Pharmaceutical has a Beta of 1.045. This is 21.51% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Collegium Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Collegium Pharmaceutical's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Collegium Pharmaceutical could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics of similar companies.Collegium Pharmaceutical is currently under evaluation in beta category among related companies.
Collegium Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Collegium Pharmaceutical from analyzing Collegium Pharmaceutical's financial statements. These drivers represent accounts that assess Collegium Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Collegium Pharmaceutical's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 688.5M | 689.2M | 652.6M | 1.0B | 934.7M | 981.4M | |
| Enterprise Value | 540.1M | 781.7M | 724.9M | 1.5B | 1.3B | 1.4B |
Collegium Pharmaceutical Institutional Holders
Institutional Holdings refers to the ownership stake in Collegium Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Collegium Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Collegium Pharmaceutical's value.| Shares | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1 M | Geode Capital Management, Llc | 2023-12-31 | 731.3 K | Victory Capital Management Inc. | 2023-12-31 | 723.3 K | Emerald Advisers, Llc | 2023-12-31 | 666.1 K | Massachusetts Financial Services Company | 2023-12-31 | 665.1 K | Hhg Plc | 2023-12-31 | 627.5 K | Rock Springs Capital Management Lp | 2023-12-31 | 562 K | Emerald Mutual Fund Advisers Trust | 2023-12-31 | 551.8 K | Millennium Management Llc | 2023-12-31 | 443.6 K | Blackrock Inc | 2023-12-31 | 5.8 M | Rubric Capital Management Lp | 2023-12-31 | 2.8 M |
Collegium Pharmaceutical returns are very sensitive to returns on the market. As the market goes up or down, Collegium Pharmaceutical is expected to follow.
Collegium Fundamentals
| Return On Equity | 0.25 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.41 % | ||||
| Current Valuation | 1.56 B | ||||
| Shares Outstanding | 32.71 M | ||||
| Shares Owned By Insiders | 1.41 % | ||||
| Shares Owned By Institutions | 98.59 % | ||||
| Number Of Shares Shorted | 6.99 M | ||||
| Price To Earning | 28.80 X | ||||
| Price To Book | 5.98 X | ||||
| Price To Sales | 2.06 X | ||||
| Revenue | 566.77 M | ||||
| Gross Profit | 345.74 M | ||||
| EBITDA | 331.83 M | ||||
| Net Income | 48.16 M | ||||
| Cash And Equivalents | 122.72 M | ||||
| Cash Per Share | 3.60 X | ||||
| Total Debt | 674.28 M | ||||
| Debt To Equity | 3.82 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 6.13 X | ||||
| Cash Flow From Operations | 274.75 M | ||||
| Short Ratio | 14.42 X | ||||
| Earnings Per Share | 1.29 X | ||||
| Target Price | 40.0 | ||||
| Number Of Employees | 197 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 1.23 B | ||||
| Total Asset | 1.14 B | ||||
| Retained Earnings | (233.19 M) | ||||
| Working Capital | 79.69 M | ||||
| Current Asset | 96.88 M | ||||
| Current Liabilities | 8.43 M | ||||
| Net Asset | 1.14 B |
About Collegium Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Collegium Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collegium Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collegium Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Collegium Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Collegium Pharmaceutical's short interest history, or implied volatility extrapolated from Collegium Pharmaceutical options trading.
Pair Trading with Collegium Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collegium Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collegium Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Collegium Stock
| 0.8 | GSTX | Graphene Solar Techn | PairCorr |
| 0.78 | IRNRF | Iron Road Limited | PairCorr |
| 0.73 | SRBBF | VPN Technologies | PairCorr |
The ability to find closely correlated positions to Collegium Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collegium Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collegium Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collegium Pharmaceutical to buy it.
The correlation of Collegium Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collegium Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collegium Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collegium Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Collegium Pharmaceutical Piotroski F Score and Collegium Pharmaceutical Altman Z Score analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Collegium Stock analysis
When running Collegium Pharmaceutical's price analysis, check to measure Collegium Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collegium Pharmaceutical is operating at the current time. Most of Collegium Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Collegium Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collegium Pharmaceutical's price. Additionally, you may evaluate how the addition of Collegium Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Collegium Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 51.976 | Earnings Share 1.29 | Revenue Per Share 16.797 | Quarterly Revenue Growth 0.155 | Return On Assets 0.1028 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.